Global Parkinson’s Disease Treatment Market Size to Worth USD 9.14 Billion By 2033 | CAGR of 6.41%
Category: HealthcareGlobal Parkinson’s Disease Treatment Market Size to Worth USD 9.14 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Parkinson’s Disease Treatment Size is to Grow from USD 4.91 Billion in 2023 to USD 9.14 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 6.41% during the projected period.
Get more details on this report -
Browse key industry insights spread across 232 pages with 115 Market data tables and figures & charts from the report on the "Parkinson’s Disease Treatment Size, Share, and COVID-19 Impact Analysis, By Drug Class (Carbidopa-Levodopa, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors, and Others), By Route of Administration (Oral, Subcutaneous, Transdermal, and Others), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/parkinsons-disease-treatment-market
A neurological disorder called Parkinson’s disease is characterized by involuntary or uncontrollable movements, such as stiffness, shaking, and difficulty in balance and coordination. Since there is now no recognized treatment for Parkinson’s disease, industry players are working on developing new drugs that may lessen the condition's symptoms. Noninvasive diagnostic imaging, like positron emission tomography (PET) scans, can help a clinician diagnose a patient. The market for Parkinson's disease medicines is being driven by the aging of the population, rising public knowledge of the condition, and the anticipated availability of new treatments. Additionally, it is projected that the market will rise in the next years due to the increasing accessibility and availability of different medications and supporting therapies for the treatment of Parkinson’s disease. Furthermore, treatments for Parkinson’s disease can cause orthostatic hypotension as well as gastrointestinal issues like nausea and vomiting during adverse effects. Neuropsychiatric illnesses are characterized by anxiety and hallucinations, which may result from dopamine's off-target effects operating in extranigral brain regions.
The carbidopa-levodopa segment is expected to dominate the market with the largest revenue share of Parkinson’s disease treatment during the projected timeframe.
Based on the drug class, the Parkinson’s disease treatment is divided into carbidopa-levodopa, dopamine agonists, monoamine oxidase type B (MAO-B) inhibitors, catechol-o-methyltransferase (COMT) inhibitors, and others. Among these, the carbidopa-levodopa segment is expected to dominate the market with the largest revenue share of Parkinson’s disease treatment during the projected timeframe. One of the best medication combinations for Parkinson's disease treatment is carbidopa- levodopa. As a second line of treatment, it is frequently utilized because it is the most effective.
The oral segment accounted for the market with the largest market share in Parkinson’s disease Treatment during the projected timeframe.
Based on the route of administration, the Parkinson’s disease treatment is divided into oral, subcutaneous, transdermal, and others. Among these, the oral segment accounted for the market with the largest market share in Parkinson’s disease treatment during the projected timeframe. Once drugs or active ingredients are taken orally, they enter the bloodstream through the digestive system and are then disseminated throughout the body. The drug, which is frequently given as a tablet, capsule, or liquid, is swallowed by the patient.
The hospital pharmacy segment is anticipated to grow at the fastest CAGR growth of Parkinson’s disease treatment during the estimated period.
Based on the distribution channels, the Parkinson’s disease treatment is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, the hospital pharmacy segment is anticipated to grow at the fastest CAGR growth of Parkinson’s disease treatment during the estimated period. Hospital pharmacies are the primary means of distribution for anti-Parkinson’s drugs, both branded and generic. The growing number of individuals with Parkinson’s disease and the ease with which various dosage forms can be acquired at hospital pharmacies are anticipated to fuel the segment's growth.
North America is expected to hold the largest share of the Parkinson’s disease treatment over the forecast period.
Get more details on this report -
North America is expected to hold the largest share of the Parkinson’s disease treatment over the forecast period. The aging population is driving up the number of persons receiving diagnoses for this ailment, which in turn is driving up demand for therapy. North America is home to cutting-edge medical facilities and technology as well as a highly developed healthcare system. This increases the need for medications because it enables an early diagnosis, encompassing therapy, and improved control of Parkinson's disease.
Asia Pacific is predicted to grow at the fastest pace in the Parkinson’s disease treatment during the projected timeframe. An increase in government funding and patient volume is anticipated to boost the regional market. Additionally, it is expected that increased R&D efforts and supportive government policies will contribute to the growth of the regional market.
Major vendors in the Parkinson’s disease treatment include Abbott Laboratories, General Electric Company, Abbvie, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Sun Pharma, Novartis AG, Olatec Therapeutics, Biotech Ltd., Amneal Pharmaceuticals LLC, Zydus Cadila, Hallamshire Physiotherapy Ltd., Wockhardt Ltd., and Others.
Recent Developments
- In January 2022, ABL Bio Inc. and Sanofi partnered to develop and market a medication for Parkinson's disease as well as additional possible indications.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Parkinson’s disease treatment market based on the below-mentioned segments:
Global Parkinson’s disease Treatment Market, By Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- Monoamine Oxidase Type B (MAO-B) Inhibitor
- Catechol-O-Methyltransferase (COMT) Inhibitor
- Others
Global Parkinson’s disease Treatment Market, By Route of Administration
- Oral
- Subcutaneous
- Transdermal
- Others
Global Parkinson’s disease Treatment Market, By Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Parkinson’s disease Treatment Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?